IN2014DN09776A - - Google Patents
Info
- Publication number
- IN2014DN09776A IN2014DN09776A IN9776DEN2014A IN2014DN09776A IN 2014DN09776 A IN2014DN09776 A IN 2014DN09776A IN 9776DEN2014 A IN9776DEN2014 A IN 9776DEN2014A IN 2014DN09776 A IN2014DN09776 A IN 2014DN09776A
- Authority
- IN
- India
- Prior art keywords
- soluble
- subject
- level
- methods
- biological sample
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3627—Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/38—Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
- A61N1/39—Heart defibrillators
- A61N1/3956—Implantable devices for applying electric shocks to the heart, e.g. for cardioversion
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Hospice & Palliative Care (AREA)
- Surgery (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting , replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT , or CRT- D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in , or stratifying a subject participating in , a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649202P | 2012-05-18 | 2012-05-18 | |
| PCT/US2013/041686 WO2013173778A1 (en) | 2012-05-18 | 2013-05-17 | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09776A true IN2014DN09776A (en) | 2015-07-31 |
Family
ID=49584355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9776DEN2014 IN2014DN09776A (en) | 2012-05-18 | 2014-11-18 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20130345805A1 (en) |
| EP (2) | EP2849729B1 (en) |
| JP (2) | JP6302896B2 (en) |
| CN (2) | CN104507383B (en) |
| AU (2) | AU2013262515B2 (en) |
| CA (1) | CA2873896A1 (en) |
| ES (1) | ES2709697T3 (en) |
| HK (1) | HK1208624A1 (en) |
| IN (1) | IN2014DN09776A (en) |
| MX (1) | MX357740B (en) |
| WO (1) | WO2013173778A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| DK2336359T3 (en) | 2002-05-09 | 2016-05-30 | Brigham & Womens Hospital | 1L1RL-1 as cardiovascular disease marker |
| ATE476657T1 (en) | 2006-04-24 | 2010-08-15 | Critical Care Diagnostics Inc | PREDICTION OF LETHALITY AND DETECTION OF SERIOUS DISEASES |
| ATE517341T1 (en) * | 2006-04-27 | 2011-08-15 | Critical Care Diagnostics Inc | INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PREDICTION OF CARDIOVASCULAR DISEASES |
| EP2482078B1 (en) | 2006-05-01 | 2016-02-03 | Critical Care Diagnostics, Inc. | Diagnosis of cardiovascular disease |
| ES2443125T3 (en) | 2008-04-18 | 2014-02-17 | Critical Care Diagnostics, Inc. | Prediction of the risk of serious adverse cardiac events |
| CN103154027B (en) | 2010-04-09 | 2016-06-29 | 重症监护诊断股份有限公司 | Soluble human ST-2 antibody and analytic process |
| JP6215713B2 (en) | 2011-03-17 | 2017-10-18 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | How to predict the risk of adverse clinical outcomes |
| AU2012284039B2 (en) | 2011-07-18 | 2017-03-30 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| EP2809392B1 (en) * | 2012-01-31 | 2016-09-14 | Cardiac Pacemakers, Inc. | Implantable device and methods for diagnosing heart failure using biomarker panel data |
| WO2013116544A1 (en) | 2012-01-31 | 2013-08-08 | Cardiac Pacemakers, Inc. | Systems and methods for controlling a cardiac resynchronisation device/therapy using biomarker panel data |
| MX357740B (en) * | 2012-05-18 | 2018-07-23 | Critical Care Diagnostics Inc | Methods for treating or predicting risk of a ventricular tachyarrhythmia event. |
| RU2019107598A (en) | 2012-08-16 | 2019-03-28 | Критикал Кэа Дайэгностикс, Инк. | METHODS FOR FORECASTING THE RISK OF DEVELOPMENT OF HYPERTENSION |
| RU2015110054A (en) | 2012-08-21 | 2016-10-10 | Критикал Кэа Дайэгностикс, Инк. | MULTIMARKER STRATIFICATION OF RISK |
| CA3103560C (en) | 2014-09-26 | 2023-01-17 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10188863B2 (en) * | 2015-02-26 | 2019-01-29 | Medtronic, Inc. | Therapy program selection for electrical stimulation therapy based on a volume of tissue activation |
| JP7009977B2 (en) * | 2017-12-25 | 2022-01-26 | 国立大学法人東海国立大学機構 | Methods, devices and computer programs for predicting the severity and prognosis of heart disease using measurements of the subject's blood VEGF-A. |
| WO2020097190A1 (en) * | 2018-11-06 | 2020-05-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of personalized treatment for cardiomyopathy and heart failure and associated diseases by measuring edema and cachexia/sarcopenia |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001218871A1 (en) | 2000-03-21 | 2001-10-03 | Takao Arai | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| DK2336359T3 (en) | 2002-05-09 | 2016-05-30 | Brigham & Womens Hospital | 1L1RL-1 as cardiovascular disease marker |
| US20060257558A1 (en) | 2003-10-31 | 2006-11-16 | Hiroshi Nomura | Plasma polymerization of atomically modified surfaces |
| JP2007523324A (en) * | 2004-02-05 | 2007-08-16 | メドトロニック・インコーポレーテッド | Method and apparatus for identifying a patient at risk for a life-threatening arrhythmia |
| ATE476657T1 (en) | 2006-04-24 | 2010-08-15 | Critical Care Diagnostics Inc | PREDICTION OF LETHALITY AND DETECTION OF SERIOUS DISEASES |
| ATE517341T1 (en) | 2006-04-27 | 2011-08-15 | Critical Care Diagnostics Inc | INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PREDICTION OF CARDIOVASCULAR DISEASES |
| EP2482078B1 (en) | 2006-05-01 | 2016-02-03 | Critical Care Diagnostics, Inc. | Diagnosis of cardiovascular disease |
| US20100055683A1 (en) | 2006-05-02 | 2010-03-04 | Critical Care Diagnostics, Inc. | Diagnosis of pulmonary and/or cardiovascular disease |
| EP2315034A3 (en) | 2006-08-04 | 2011-08-17 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on GDF-15 |
| EP1884777A1 (en) * | 2006-08-04 | 2008-02-06 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on GDF-15 |
| ATE533061T1 (en) * | 2007-08-03 | 2011-11-15 | Brahms Gmbh | METHOD FOR DIAGNOSING BACTERIAL INFECTIONS |
| WO2009036011A2 (en) * | 2007-09-11 | 2009-03-19 | The Department Of Veterans Affairs | Markers for ventricular arrhythmia |
| EP2107377A1 (en) * | 2008-04-04 | 2009-10-07 | BRAHMS Aktiengesellschaft | Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events |
| ES2443125T3 (en) | 2008-04-18 | 2014-02-17 | Critical Care Diagnostics, Inc. | Prediction of the risk of serious adverse cardiac events |
| GB0818650D0 (en) | 2008-10-10 | 2008-11-19 | Uni I Oslo | Methods |
| EP3178846B1 (en) * | 2010-02-17 | 2018-08-22 | Cedars-Sinai Medical Center | Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury |
| CN103154027B (en) | 2010-04-09 | 2016-06-29 | 重症监护诊断股份有限公司 | Soluble human ST-2 antibody and analytic process |
| JP6215713B2 (en) | 2011-03-17 | 2017-10-18 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | How to predict the risk of adverse clinical outcomes |
| AU2012284039B2 (en) | 2011-07-18 | 2017-03-30 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| MX357740B (en) * | 2012-05-18 | 2018-07-23 | Critical Care Diagnostics Inc | Methods for treating or predicting risk of a ventricular tachyarrhythmia event. |
| RU2019107598A (en) | 2012-08-16 | 2019-03-28 | Критикал Кэа Дайэгностикс, Инк. | METHODS FOR FORECASTING THE RISK OF DEVELOPMENT OF HYPERTENSION |
| RU2015110054A (en) | 2012-08-21 | 2016-10-10 | Критикал Кэа Дайэгностикс, Инк. | MULTIMARKER STRATIFICATION OF RISK |
-
2013
- 2013-05-17 MX MX2014013995A patent/MX357740B/en active IP Right Grant
- 2013-05-17 EP EP13790571.7A patent/EP2849729B1/en not_active Not-in-force
- 2013-05-17 JP JP2015512902A patent/JP6302896B2/en not_active Expired - Fee Related
- 2013-05-17 CN CN201380037345.8A patent/CN104507383B/en not_active Expired - Fee Related
- 2013-05-17 WO PCT/US2013/041686 patent/WO2013173778A1/en active Application Filing
- 2013-05-17 EP EP18193293.0A patent/EP3434260A1/en not_active Withdrawn
- 2013-05-17 CA CA2873896A patent/CA2873896A1/en not_active Abandoned
- 2013-05-17 ES ES13790571T patent/ES2709697T3/en active Active
- 2013-05-17 AU AU2013262515A patent/AU2013262515B2/en not_active Ceased
- 2013-05-17 US US13/897,249 patent/US20130345805A1/en not_active Abandoned
- 2013-05-17 CN CN201810869357.1A patent/CN109212223B/en not_active Expired - Fee Related
-
2014
- 2014-11-18 IN IN9776DEN2014 patent/IN2014DN09776A/en unknown
-
2015
- 2015-09-23 HK HK15109315.2A patent/HK1208624A1/en unknown
-
2016
- 2016-12-06 US US15/370,049 patent/US10408845B2/en not_active Expired - Fee Related
-
2018
- 2018-03-05 JP JP2018038175A patent/JP6600709B2/en not_active Expired - Fee Related
- 2018-06-12 AU AU2018204145A patent/AU2018204145A1/en not_active Abandoned
-
2019
- 2019-09-06 US US16/563,510 patent/US11340236B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018204145A1 (en) | 2018-06-28 |
| CN104507383A (en) | 2015-04-08 |
| US20190391162A1 (en) | 2019-12-26 |
| CN109212223B (en) | 2021-11-12 |
| JP2018119976A (en) | 2018-08-02 |
| JP6600709B2 (en) | 2019-10-30 |
| WO2013173778A1 (en) | 2013-11-21 |
| AU2013262515A1 (en) | 2014-12-04 |
| US20130345805A1 (en) | 2013-12-26 |
| AU2013262515B2 (en) | 2018-03-15 |
| CN109212223A (en) | 2019-01-15 |
| EP2849729A1 (en) | 2015-03-25 |
| CA2873896A1 (en) | 2013-11-21 |
| EP2849729A4 (en) | 2016-01-20 |
| EP2849729B1 (en) | 2018-11-14 |
| EP3434260A1 (en) | 2019-01-30 |
| US20170146552A1 (en) | 2017-05-25 |
| JP6302896B2 (en) | 2018-03-28 |
| JP2015520371A (en) | 2015-07-16 |
| CN104507383B (en) | 2018-08-28 |
| US11340236B2 (en) | 2022-05-24 |
| ES2709697T3 (en) | 2019-04-17 |
| US10408845B2 (en) | 2019-09-10 |
| HK1208624A1 (en) | 2016-03-11 |
| MX2014013995A (en) | 2015-09-04 |
| MX357740B (en) | 2018-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09776A (en) | ||
| AU2017225061B2 (en) | Biomarkers and methods of treating PD-1 and PD-L1 related conditions | |
| MX362514B (en) | Diagnostic assays and kits for detection of folate receptor 1. | |
| WO2016196298A8 (en) | Therapeutic and diagnostic methods for cancer | |
| MX2014005800A (en) | Human notch receptor mutations and their use. | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| WO2012141844A3 (en) | Methods predicting risk of an adverse clinical outcome | |
| AU2017245629A1 (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| ATE510583T1 (en) | DEVICE FOR IDENTIFYING ELECTRODE COMBINATIONS IN NEUROSTIMULATION THERAPY | |
| EP4406589A3 (en) | Method for adjusting a system for stimulating a hypoglossal nerve | |
| MX2016013910A (en) | Cancer treatment. | |
| WO2015014794A8 (en) | Use of alpha-crystallin b (cryab) in the assessment of heart failure | |
| WO2017216323A3 (en) | Marker sequences for managing the therapy of rheumatoid arthritis patients | |
| GB2552271A (en) | A method for diagnosing lung cancer | |
| WO2015169973A3 (en) | Marker sequences for diagnosing and stratifying systemic sclerosis patients | |
| WO2015125027A3 (en) | Kit and method for detecting bladder cancer | |
| WO2019066617A3 (en) | Anti-c-met antibody and uses thereof | |
| WO2021062085A8 (en) | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies | |
| WO2014023808A3 (en) | Method for evaluating a cancer patient for propensity to respond to a therapy | |
| HK1140797A1 (en) | Matrix marker model and methods for assessing and treating rheumatoid arthritis | |
| EP2846285A3 (en) | Risk stratification of suspected AMI patients | |
| WO2012129395A3 (en) | Diagnosis and treatment of prostate cancer | |
| WO2017053763A3 (en) | ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) | |
| WO2018200473A8 (en) | Detection and targeting of tumor-promoting neutrophils | |
| WO2014042148A8 (en) | Cancer marker and application thereof |